Supplementary Materials

The PDF file includes:

  • Fig. S1. CONSORT diagram for CheckMate275 and IMvigor210.
  • Fig. S2. Loss of ARID1A enhances the immunogenicity of bladder tumor cells.
  • Fig. S3. Patients harboring ARID1A gene mutation have higher TMB.
  • Fig. S4. Analysis of TGFβ1 and PD-L1 expression in patients with and without ARID1A mutations.
  • Fig. S5. TLS in baseline tumor tissues correlated with improved response in the discovery cohort.
  • Fig. S6. CXCL13−/− mice are resistant to anti–PD-1 therapy.
  • Fig. S7. Combination of ARID1A mutation and baseline expression of CXCL13 in the tumor tissue predicts performance of ICT.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Data file S1 (Microsoft Excel format). Patient characteristics with correlative assays performed.
  • Data file S2 (Microsoft Excel format). Expression data of NanoString Gene Panel.
  • Data file S3 (Microsoft Excel format). Antibodies used for murine CyTOF analysis.